Advertisement

Topics

EMA committee recommends approval of Bristol─Myers Squibb's Opdivo plus low─dose Yervoy as first─line treatment for RCC

15:50 EST 16 Nov 2018 | PharmaBiz

Bristol─Myers Squibb Company has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending approval of the Opdivo (nivolumab)

Original Article: EMA committee recommends approval of Bristol─Myers Squibb's Opdivo plus low─dose Yervoy as first─line treatment for RCC

NEXT ARTICLE

More From BioPortfolio on "EMA committee recommends approval of Bristol─Myers Squibb's Opdivo plus low─dose Yervoy as first─line treatment for RCC"

Advertisement
Quick Search
Advertisement
Advertisement